%0 Journal Article %1 Tuma2009 %A Tuma, Rabiya %D 2009 %J Journal of the National Cancer Institute %K AntineoplasticAgents AntineoplasticAgents:therapeuticuse ClinicalTrialsasTopic DataInterpretation Disease-FreeSurvival Humans KidneyNeoplasms KidneyNeoplasms:drugtherapy Neoplasms Neoplasms:drugtherapy Statistical TreatmentOutcome %N 21 %P 1439-41 %R 10.1093/jnci/djp399 %T Progression-free survival remains debatable endpoint in cancer trials. %U http://www.ncbi.nlm.nih.gov/pubmed/19828873 %V 101 %@ 1460-2105

@article{Tuma2009, added-at = {2023-02-03T11:44:35.000+0100}, author = {Tuma, Rabiya}, biburl = {https://www.bibsonomy.org/bibtex/28276b2ecaa08a48154020142a43f4a02/jepcastel}, doi = {10.1093/jnci/djp399}, interhash = {ad48dd9914038b176db04bf3c3218231}, intrahash = {8276b2ecaa08a48154020142a43f4a02}, isbn = {1460-2105}, issn = {1460-2105}, journal = {Journal of the National Cancer Institute}, keywords = {AntineoplasticAgents AntineoplasticAgents:therapeuticuse ClinicalTrialsasTopic DataInterpretation Disease-FreeSurvival Humans KidneyNeoplasms KidneyNeoplasms:drugtherapy Neoplasms Neoplasms:drugtherapy Statistical TreatmentOutcome}, month = {11}, note = {5434<m:linebreak></m:linebreak>JID: 7503089; 0 (Antineoplastic Agents); 2009/10/14 [aheadofprint]; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència}, number = 21, pages = {1439-41}, pmid = {19828873}, timestamp = {2023-02-03T11:44:35.000+0100}, title = {Progression-free survival remains debatable endpoint in cancer trials.}, url = {http://www.ncbi.nlm.nih.gov/pubmed/19828873}, volume = 101, year = 2009 }